Vistagen Therapeutics, Inc. revenue
Vistagen Therapeutics, Inc.'s revenue was $1.3m in fiscal 2026, up 161.1% on the year before. Since fiscal 2011 ($2.1m) it has grown at a compound -4.0% a year. Over the last twelve months it was $2.5m.
Revenue history
| Fiscal year | 2011Mar 2011 | 2012Mar 2012 | 2013Mar 2013 | 2016Mar 2016 | 2017Mar 2017 | 2018Mar 2018 | 2020Mar 2020 | 2021Mar 2021 | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,071 | 1,342 | 200 | 0 | 1,250 | 0 | 0 | 1,090 | 1,109 | −227 | 1,064 | 486 | 1,269 | 2,502 |
| Growth on the year before | — | −35.2% | −85.1% | −100.0% | — | −100.0% | — | — | +1.8% | −120.5% | — | −54.3% | +161.1% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Vistagen Therapeutics, Inc. | $2.5m | 287.3% | — |
| Korro Bio, Inc. | $2.4m | -62.1% | -53.7% |
| Collplant Biotechnologies Ltd | $2.4m | 360.4% | — |
| Upstream Bio, Inc. | $3.2m | 16.0% | — |
| Xenetic Biosciences, Inc. | $3.3m | 33.3% | 14.7% |
| Korsana Biosciences, Inc. | $1.9m | -12.6% | — |
Compare with peers
- Korro Bio, Inc. revenue
- Collplant Biotechnologies Ltd revenue
- Upstream Bio, Inc. revenue
- Xenetic Biosciences, Inc. revenue
- Korsana Biosciences, Inc. revenue
Head to head: KRRO vs VTGNCLGN vs VTGNUPB vs VTGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies